title: Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts.
abstract: Conflicting data exist regarding an advantage of drug-eluting stents (DES) over bare metal stents (BMS) in catheter-based treatment of saphenous vein graft (SVG) stenoses. This study was undertaken to compare the efficacy of these modalities in that lesion subset. The DES group consisted of 138 cases with 183 lesions (sirolimus-eluting stents, n = 117; paclitaxel-eluting stents, n = 66) and the BMS group consisted of 344 cases with 478 lesions that were followed to 1 year. We examined a composite end point that comprised death, Q-wave myocardial infarction, and target lesion revascularization. More BMS were deployed per patient (p <0.001) and the diameters of BMS deployed was significantly greater (p <0.001). Peak postprocedure values of creatine kinase-MB (p = 0.003) and troponin I (p = 0.05) were higher in BMS. At 1 year there was no significant superiority of DES over BMS with regard to hard end points (death and Q-wave myocardial infarction). In conclusion, this study indicates that both DES and BMS for SVG disease provide acceptably safe and efficacious results, but unlike the case in native coronary arteries, DES use does not reduce the frequency of the need for repeat revascularization.
authors: Cardiovascular Research Institute, Washington Hospital Center, Washington, DC, USA.
authors: Teruo
authors: T
authors: Okabe
authors: Joseph
authors: J
authors: Lindsay
authors: Ashesh N
authors: AN
authors: Buch
authors: Daniel H
authors: DH
authors: Steinberg
authors: Probal
authors: P
authors: Roy
authors: Tina L Pinto
authors: TL
authors: Slottow
authors: Kimberly
authors: K
authors: Smith
authors: Rebecca
authors: R
authors: Torguson
authors: Zhenyi
authors: Z
authors: Xue
authors: Lowell F
authors: LF
authors: Satler
authors: Kenneth M
authors: KM
authors: Kent
authors: Augusto D
authors: AD
authors: Pichard
authors: Neil J
authors: NJ
authors: Weissman
authors: Ron
authors: R
authors: Waksman
mesh_terms: D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D052279:Creatine Kinase, MB Form / Q000097:blood; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000601:surgery*; D006801:Humans; D008297:Male; D008670:Metals; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000601:surgery*; D012189:Retrospective Studies; D012501:Saphenous Vein / Q000637:transplantation*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D008670:Metals; D052279:Creatine Kinase, MB Form